UK government advisors have recommended that prostate cancer screening should only be offered to a few thousand men with a dangerous genetic variant and a family history of the disease, rejecting calls for a more widespread national programme.
The decision by the UK National Screening Committee means that, unlike breast, bowel and lung cancer, prostate cancer will not have a national screening programme. Prostate cancer is the most common cancer in the UK, but the advisors argued that the risks of overdiagnosis and overtreatment for low-risk men outweigh the benefits for the general population.
“UK advisors recommend limiting prostate cancer screening to a few thousand high-risk men, sparking criticism that thousands face avoidable deaths.”
Critics, including the Daily Mail, have warned that thousands of men could face avoidable deaths as a result. The newspaper described the move as condemning men to unnecessary deaths, highlighting that early detection dramatically improves survival rates.
Under the new guidance, only men with a high-risk genetic variant and a strong family history of cancer will be eligible for screening. This represents a small fraction of the male population, with estimates suggesting just a few thousand individuals would qualify.
The advisors' recommendation now goes to the UK government for a final decision. If accepted, it would mean no change to the current policy, which relies on men requesting a PSA blood test from their GP if they have symptoms or concerns.
What This Means For You For most men in the UK, there will be no routine prostate cancer screening. Those with a family history of prostate cancer or a known genetic variant should speak to their GP about individual risk. The decision may particularly affect men in their 50s and 60s, where risk is highest. Campaigners argue that without a screening programme, many cases will be diagnosed late, reducing treatment options and survival chances.